Last updated on 4-11-2022 by Géraldine Daneau
Authors
Jung, Andreas; Orenti, Annalisa; Dunlevy, Fiona; Aleksejeva, Elina; Bakkeheim, Egil; Bobrovnichy, Vladimir; Siobhán B Carr; Colombo, Carla; Corvol, Harriet; Cosgriff, Rebecca; Géraldine Daneau; Dogru, Deniz; Drevinek, Pavel; Vukic, Andrea Dugac; Fajac, Isabelle; Fox, Alice; Fustik, Stojka; Gulmans, Vincent; Harutyunyan, Satenik; Hatziagorou, Elpis; Kasmi, Irena; Kayserová, Hana; Kondratyeva, Elena; Krivec, Uroš; Makukh, Halyna; Malakauskas, Kestutis; Edward F McKone; Mei-Zahav, Meir; de Monestrol, Isabelle; Olesen, Hanne Vebert; Padoan, Rita; Parulava, Tsitsino; Pastor-Vivero, Maria Dolores; Pereira, Luísa; Petrova, Guergana; Pfleger, Andreas; Pop, Liviu; Jacqui G van Rens; Rodic, Milan; Schlesser, Marc; Storms, Valérie; Turcu, Oxana; Woz Niacki, Lukasz; Yiallouros, Panayiotis; Zolin, Anna; Damian G Downey; Naehrlich, LutzKeywords
Article written during project(s) :
Abstract:
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes.
METHODS: In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis.
RESULTS: Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0-18.4). M…